Speech-Language Pathologists in Sparta, NC Accepting Medicare

2 Speech-Language Pathologists found. Showing 1 - 2

Mrs. Deborah Lynn Brady, MA CCC SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 289 Westview Dr, Sparta, NC 28675 Phone: 336-372-4402    Fax: 336-372-7420

Dale Marie Sandusky, MA, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 179 Combs St, Sparta, NC 28675 Phone: 336-372-2441

News Archive

Compound from soil bacteria could translate into new drug lead for TB

A new treatment for tuberculosis (TB) is set to be developed using compounds derived from bacteria that live in soil - according an international collaboration of researchers, including the University of Warwick.

Final FDA approval for generic version of antiretroviral Zerit capsules

Mylan Inc. has announced that Matrix Laboratories Limited, its India-based subsidiary in which it holds a 71.5% controlling interest, received final approval from the U.S. Food and Drug Administration (FDA) on December 29, for its Abbreviated New Drug Application (ANDA) for Stavudine Capsules USP, 15 mg, 20 mg, 30 mg and 40 mg.

Siah2 Gene Control could Help Treat Melanomas More Effectively

To develop improved cancer immunotherapies, it is essential to understand how cancers shut down the natural immune response to foreign antigens. This current study demonstrates how mice lacking the Siah2 gene, fail to develop BRAF-mutation carrying melanoma from the corresponding cells, completely rejecting them. This could help in boosting the anticancer effect of existing specific immune checkpoint inhibitors, such as anti-PD-1 drugs.

Rising temperature induces key changes in dengue virus

Researchers have discovered that rising temperature induces key changes in the dengue virus when it enters its human host, and the findings represent a new approach for designing vaccines against the aggressive mosquito-borne pathogen.

Belgian FAMHP approves Oncolytics' Phase 3 combination trial of REOLYSIN in head and neck cancers

Oncolytics Biotech Inc. today announced that it has received approval from the Belgian Federal Agency for Medicines and Health Products (FAMHP) to conduct its Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers. This is the same trial that was agreed to by U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process and the U.K. Medicines and Healthcare products Regulatory Agency (MHRA).

Read more Medical News

› Verified 4 days ago